LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX)
CUSIP: 528872302
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 444,558,533
- Total 13F shares
- 265,818,368
- Share change
- -30,807,274
- Total reported value
- $122,485,430
- Put/Call ratio
- 24%
- Price per share
- $0.46
- Number of holders
- 124
- Value change
- -$18,132,306
- Number of buys
- 64
- Number of sells
- 61
Quarterly Holders Quick Answers
What is CUSIP 528872302?
CUSIP 528872302 identifies LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 528872302:
Top shareholders of LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Artal Group S.A. |
13F
|
Company |
31%
|
136,180,481
|
$100,773,556 | — | 31 Dec 2024 | |
| Siren, L.L.C. |
3/4/5
13F
|
Director, 10%+ Owner · Individual |
8.8%
from 13F
|
35,402,689
|
$92,755,045 | — | 25 Jul 2024 | |
| FMR LLC |
13F
|
Company |
12%
|
51,970,455
|
$38,380,181 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
2.3%
|
10,333,158
|
$7,631,037 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.2%
|
9,881,728
|
$7,302,597 | — | 31 Dec 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2%
|
8,988,421
|
$6,637,949 | — | 31 Dec 2024 | |
| Invus US Partners LLC |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
5,782,749
|
$6,090,969 | — | 05 Aug 2022 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
1.7%
|
7,558,621
|
$5,582,040 | — | 31 Dec 2024 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.5%
|
6,604,150
|
$4,877,165 | — | 31 Dec 2024 | |
| Lonnel Coats |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
2,109,255
mixed-class rows
|
$3,507,748 | — | 28 Feb 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.79%
|
3,521,255
|
$2,601,084 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.61%
|
2,718,248
|
$2,007,426 | — | 31 Dec 2024 | |
| NEA Management Company, LLC |
13F
|
Company |
0.54%
|
2,382,286
|
$1,759,318 | — | 31 Dec 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.35%
|
1,550,000
|
$1,144,675 | — | 31 Dec 2024 | |
| Jeffrey L. Wade |
3/4/5
|
President and COO |
—
mixed-class rows
|
729,441
mixed-class rows
|
$1,106,796 | — | 08 Jul 2024 | |
| PINNACLE ASSOCIATES LTD |
13F
|
Company |
0.32%
|
1,425,292
|
$1,052,578 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.29%
|
1,308,651
|
$966,439 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.27%
|
1,191,091
|
$879,621 | — | 31 Dec 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.25%
|
1,103,840
|
$815,186 | — | 31 Dec 2024 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.19%
|
863,255
|
$637,514 | — | 31 Dec 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.19%
|
850,268
|
$627,923 | — | 31 Dec 2024 | |
| B. Kassler Taub |
3/4/5
|
SVP, Regulatory & QA |
—
mixed-class rows
|
431,995
mixed-class rows
|
$597,845 | — | 28 Feb 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.17%
|
747,996
|
$552,395 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.15%
|
686,117
|
$507,040 | — | 31 Dec 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.12%
|
550,891
|
$406,833 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.12%
|
540,207
|
$398,942 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.12%
|
526,150
|
$388,562 | — | 31 Dec 2024 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.11%
|
480,822
|
$355,087 | — | 31 Dec 2024 | |
| BBR PARTNERS, LLC |
13F
|
Company |
0.11%
|
470,000
|
$347,095 | — | 31 Dec 2024 | |
| Ph.D. Alan J. Main |
3/4/5
|
EVP, Innov & Chem Sciences |
—
mixed-class rows
|
1,228,681
mixed-class rows
|
$318,646 | — | 28 Feb 2025 | |
| Swiss National Bank |
13F
|
Company |
0.1%
|
426,600
|
$315,044 | — | 31 Dec 2024 | |
| VIRTUS ADVISERS, LLC |
13F
|
Company |
0.1%
|
425,269
|
$314,061 | — | 31 Dec 2024 | |
| Brian T. Corrigan |
3/4/5
|
SVP, Regulatory & QA |
—
mixed-class rows
|
1,121,660
mixed-class rows
|
$300,602 | — | 13 Feb 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.08%
|
353,508
|
$261,242 | — | 31 Dec 2024 | |
| Thomas Garner |
3/4/5
|
SVP, Chief Commercial Officer |
—
mixed-class rows
|
454,260
mixed-class rows
|
$239,236 | — | 08 Feb 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.07%
|
315,659
|
$233,587 | — | 31 Dec 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.07%
|
314,919
|
$232,569 | — | 31 Dec 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.07%
|
314,404
|
$232,187 | — | 31 Dec 2024 | |
| Robert J. Lefkowitz MD |
3/4/5
|
Director |
—
mixed-class rows
|
130,080
mixed-class rows
|
$223,156 | — | 13 May 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.06%
|
246,121
|
$181,760 | — | 31 Dec 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.05%
|
243,316
|
$179,690 | — | 31 Dec 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.05%
|
229,376
|
$169,394 | — | 31 Dec 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.05%
|
220,264
|
$162,665 | — | 31 Dec 2024 | |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM |
13F
|
Company |
0.04%
|
195,215
|
$144,166 | — | 31 Dec 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.03%
|
153,151
|
$113,013 | — | 31 Dec 2024 | |
| Ph.D. Kiernan Seth |
3/4/5
|
VP, Chief Commercial Officer |
—
mixed-class rows
|
379,163
mixed-class rows
|
$104,343 | — | 28 Feb 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
136,407
|
$100,669 | — | 31 Dec 2024 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.03%
|
112,853
|
$83,344 | — | 31 Dec 2024 | |
| Legal & General Group Plc |
13F
|
Company |
0.03%
|
111,403
|
$82,271 | — | 31 Dec 2024 | |
| Lombard Odier SCmA Compagnie |
13F
|
Individual |
0.02%
|
110,000
|
$81,235 | — | 31 Dec 2024 |
Institutional Holders of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) as of Q1 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.